Conversely, in cancers such as BLCA, KIRC, KIRP, LUSC and STAD, an elevated expression of GLIPR2 was associated with an increased risk of mortality (Figure 7B) Integrated prognostic and diagnostic analysis identified LUAD, LUSC, and CESC as cancers most likely to benefit from the GLIPR2 biomarker (Figure 7C). This evidence concerns the gene GLIPR2 and bladder transitional cell carcinoma.